This article reviews mobile medical applications that are commercially available in the United States or European Union (EU) and are (1) associated with published data of clinical outcomes in the peer-reviewed literature during the past 5 years, (2) cleared by the US Food and Drug Administration (FDA) in the United States, or (3) a recipient of a CE (Conformité Européenne) mark by the EU. Many of these applications have been shown to positively affect outcomes in the short term, but long-term studies are needed. Until more data are available, consumers and professionals can consider guidance based on FDA/CE status.
|Original language||English (US)|
|Number of pages||23|
|Journal||Endocrinology and Metabolism Clinics of North America|
|State||Published - Dec 1 2016|
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism